Crossmark

Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes

Crossref DOI link: https://doi.org/10.1186/s12936-015-0794-0

Published Online: 2015-07-15

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Poespoprodjo, Jeanne Rini

Fobia, Wendelina

Kenangalem, Enny

Lampah, Daniel A

Sugiarto, Paulus

Tjitra, Emiliana

Anstey, Nicholas M

Price, Richard N
Funding

Funding for this research was provided by:

Wellcome Trust (091625)

Wellcome Trust (099875)

National Health and Medical Research Council of Australia (1042072)